Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|August 23, 2014
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myelomaDonna E Reece, Esther Masih-Khan, Eshetu G Atenafu, et al.
Blood|February 15, 2012
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosisJoseph R Mikhael, Steven R Schuster, Victor H Jimenez-Zepeda, et al.
British Journal of Haematology|November 26, 2013
Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institutionVictor H Jimenez-Zepeda, Norman Franke, Donna E Reece, et al.
British Journal of Haematology|April 19, 2013
D(T)PACE as salvage therapy for aggressive or refractory multiple myelomaAlina S Gerrie, Joseph R Mikhael, Lu Cheng, et al.
Plos One|May 17, 2018
Internal medicine trainees' knowledge and confidence in using the American Society of Hematology Choosing Wisely guidelines in hemostasis, thrombosis, and non-malignant hematologyAriela L Marshall, Sarah Jenkins, Amy S Oxentenko, et al.
British Journal of Haematology|November 28, 2008
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access programJoseph R Mikhael, Andrew R Belch, H Miles Prince, et al.
British Journal of Haematology|February 17, 2015
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaJoseph R Mikhael, Craig B Reeder, Edward N Libby, et al.
Patient Preference and Adherence|March 8, 2022
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United StatesDaniel Auclair, Carol Mansfield, Mark A Fiala, et al.
British Journal of Haematology|November 19, 2013
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemiaAneel Paulus, Kasyapa Chitta, Sharoon Akhtar, et al.
Blood Cancer Journal|March 6, 2023
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patientsRodrigo Fonseca, Mariano Arribas, Julia E Wiedmeier-Nutor, et al.
Pageof 5